OBJECTIVES: Enhanced inflammation is evident in HIV infection, even with virological suppression. Outside HIV infection, studies show an independent association between higher total bilirubin and better endothelial function as well as a lower prevalence of coronary heart disease, possibly as a consequence of the anti-inflammatory and antioxidant effect of bilirubin. The aim of this study was to determine whether such an association exists in HIV-infected individuals. METHODS: A cross-sectional study was performed in HIV-1-infected adults on stable antiretroviral therapy (ART) to determine if a relationship exists between total bilirubin and endothelial function [flow-mediated dilation (FMD) of the brachial artery], inflammation [interleukin-6 (IL-6), soluble tumour necrosis factor receptors, C-reactive protein, and adhesion molecules], coagulation markers (fibrinogen and D-dimer) and oxidative stress (F (2) -isoprostanes). Endpoints were compared based on total bilirubin levels and atazanavir status using distributionally appropriate, two-sample tests. Correlation coefficients were determined between total bilirubin and endpoints. Linear regression was used to model the relationship between total bilirubin (and atazanavir status) and FMD. RESULTS: A total of 98 adults were included in the study. Total bilirubin was higher in the atazanavir group when compared to the non-atazanavir group [median (interquartile range) 1.8 (1.1-2.6) vs. 0.6 (0.4-1.4) mg/dL; P < 0.01] as were insulin, the homeostasis model assessment of insulin resistance (HOMA-IR) and fibrinogen. Total bilirubin was positively correlated with fibrinogen and was not correlated with other outcomes. After adjustment, neither total bilirubin nor atazanavir status was associated with FMD. CONCLUSIONS: In virologically suppressed, HIV-infected adults on stable ART, neither total bilirubin nor atazanavir use was associated with improved endothelial function as measured using FMD, inflammation or oxidative stress as measured using biomarkers.
OBJECTIVES: Enhanced inflammation is evident in HIV infection, even with virological suppression. Outside HIV infection, studies show an independent association between higher total bilirubin and better endothelial function as well as a lower prevalence of coronary heart disease, possibly as a consequence of the anti-inflammatory and antioxidant effect of bilirubin. The aim of this study was to determine whether such an association exists in HIV-infected individuals. METHODS: A cross-sectional study was performed in HIV-1-infected adults on stable antiretroviral therapy (ART) to determine if a relationship exists between total bilirubin and endothelial function [flow-mediated dilation (FMD) of the brachial artery], inflammation [interleukin-6 (IL-6), soluble tumour necrosis factor receptors, C-reactive protein, and adhesion molecules], coagulation markers (fibrinogen and D-dimer) and oxidative stress (F (2) -isoprostanes). Endpoints were compared based on total bilirubin levels and atazanavir status using distributionally appropriate, two-sample tests. Correlation coefficients were determined between total bilirubin and endpoints. Linear regression was used to model the relationship between total bilirubin (and atazanavir status) and FMD. RESULTS: A total of 98 adults were included in the study. Total bilirubin was higher in the atazanavir group when compared to the non-atazanavir group [median (interquartile range) 1.8 (1.1-2.6) vs. 0.6 (0.4-1.4) mg/dL; P < 0.01] as were insulin, the homeostasis model assessment of insulin resistance (HOMA-IR) and fibrinogen. Total bilirubin was positively correlated with fibrinogen and was not correlated with other outcomes. After adjustment, neither total bilirubin nor atazanavir status was associated with FMD. CONCLUSIONS: In virologically suppressed, HIV-infected adults on stable ART, neither total bilirubin nor atazanavir use was associated with improved endothelial function as measured using FMD, inflammation or oxidative stress as measured using biomarkers.
Authors: Jing-Ping Lin; Christopher J O'Donnell; Johannes P Schwaiger; L Adrienne Cupples; Arno Lingenhel; Steven C Hunt; Song Yang; Florian Kronenberg Journal: Circulation Date: 2006-09-25 Impact factor: 29.690
Authors: Pavitra Keshavan; Tracy L Deem; Sandy J Schwemberger; George F Babcock; Joan M Cook-Mills; Stephen D Zucker Journal: J Immunol Date: 2005-03-15 Impact factor: 5.422
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Todd S Perlstein; Reena L Pande; Joshua A Beckman; Mark A Creager Journal: Arterioscler Thromb Vasc Biol Date: 2007-11-01 Impact factor: 8.311
Authors: Corrilynn O Hileman; Teresa L Carman; Norma J Storer; Danielle E Labbato; Cynthia A White; Grace A McComsey Journal: AIDS Res Hum Retroviruses Date: 2011-10-17 Impact factor: 1.723
Authors: Andrew N Phillips; Andrew Carr; Jacquie Neuhaus; Fehmida Visnegarwala; Ronald Prineas; William J Burman; Ian Williams; Fraser Drummond; Daniel Duprez; Waldo H Belloso; Frank-Detlef Goebel; Birgit Grund; Angelos Hatzakis; Jose Vera; Jens D Lundgren Journal: Antivir Ther Date: 2008
Authors: James H Stein; Heather J Ribaudo; Howard N Hodis; Todd T Brown; Thuy Tien T Tran; Mingzhu Yan; Elizabeth Lauer Brodell; Theodore Kelesidis; Grace A McComsey; Michael P Dube; Robert L Murphy; Judith S Currier Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Joshua A Beckman; Brian R Wood; Kevin L Ard; Christin N Price; Daniel A Solomon; Jonah P Zuflacht; Jessica Milian; Joshua C Prenner; Paul E Sax Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240
Authors: Vincent C Marconi; Meredith S Duncan; Kaku So-Armah; Vincent Lo Re; Joseph K Lim; Adeel A Butt; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; Charles W Alcorn; Jeffrey Lennox; Joshua A Beckman; Amy Justice; Matthew Freiberg Journal: J Am Heart Assoc Date: 2018-05-02 Impact factor: 5.501